Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - pipéracilline sodique 4170 mg - eq. pipéracilline 4000 mg; tazobactam sodique 536 mg - eq. tazobactam 500 mg - poudre pour solution pour perfusion - 4 g - 500 mg - pipéracilline sodique 4170 mg; tazobactam sodique 536 mg - piperacillin and enzyme inhibitor

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stravencon - pipéracilline sodique 4169.87 mg - eq. pipéracilline 4000 mg; tazobactam sodique 536.58 mg - eq. tazobactam 500 mg - poudre pour solution pour perfusion - 4 g - 500 mg - pipéracilline sodique 4169.87 mg; tazobactam sodique 536.58 mg - piperacillin and enzyme inhibitor

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - piperacillin sodium, quantity: 2.085 g (equivalent: piperacillin, qty g); tazobactam sodium, quantity: 268.3 mg (equivalent: tazobactam, qty mg) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - pipéracilline sodique 4253,1 mg - eq. pipéracilline 4 g; tazobactam sodique 547,33 mg - eq. tazobactam 500 mg - poudre pour solution injectable/pour perfusion - 4 g - 500 mg - tazobactam sodique 547.33 mg; pipéracilline sodique 4253.1 mg - piperacillin and enzyme inhibitor

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tazobactam sodium, quantity: 536.6 mg (equivalent: tazobactam, qty mg); piperacillin sodium, quantity: 4.17 g (equivalent: piperacillin, qty g) - injection, powder for - excipient ingredients: - piperacillin/tazobactam kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections. 2. urinary tract infections (complicated and uncomplicated). 3. intra-abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections.,,children under the age of 12 years:,in hospitalised children aged 2 to 12 years, piperacillin/tazobactam kabi injection is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.,while piperacillin/tazobactam kabi injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piperacillin/tazobactam. therapy with piperacillin/tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,in serious infections, presumptive therapy with piperacillin/tazobactam kabi may be initiated before susceptibility test results are available.,combination therapy with piperacillin/tazobactam kabi and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - piperacillin sodium 4170 mg - eq. piperacillin 4000 mg; tazobactam sodium 536 mg - eq. tazobactam 500 mg - powder for solution for infusion - 4 g - 500 mg - piperacillin sodium 4170 mg; tazobactam sodium 536 mg - piperacillin and enzyme inhibitor

Israel - hebraisk - Ministry of Health

bioavenir ltd, israel - piperacillin as sodium salt; tazobactam as sodium salt - אבקה להכנת תמיסה לזריקה - tazobactam as sodium salt 500 mg; piperacillin as sodium salt 4000 mg - tazobactam - tazobactam - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms.tazo-pip avenir in combination with an aminoglycoside, is indicated for the treatment of suspected bacterial infections in neutropenic adults and children. appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - pipéracilline sodique 4170 mg - eq. pipéracilline 4000 mg; tazobactam sodique 536,6 mg - eq. tazobactam 500 mg - poudre pour solution pour perfusion - 4 g - 0,5 g - pipéracilline sodique 4170 mg; tazobactam sodique 536.6 mg - piperacillin and enzyme inhibitor

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - piperacillin sodium, quantity: 4170 mg (equivalent: piperacillin, qty 4000 mg); tazobactam sodium, quantity: 540 mg (equivalent: tazobactam, qty 500 mg) - injection, powder for - excipient ingredients: nitrogen - piptaz-aft is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections,children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz-aft is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while piptaz-aft is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to piptaz-aft. therapy with piptaz-aft, however, may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued. in serious infections, presumptive therapy with piptaz-aft may be initiated before susceptibility test results are available. combination therapy with piptaz-aft and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - piperacillin sodium, quantity: 4.2 g (equivalent: piperacillin, qty 4 g); tazobactam sodium, quantity: 0.54 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - tazopip is indicated in the treatment of serious bacterial infections caused by susceptible strains of beta -lactamase producing organisms in the conditions as listed: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated). 3.intra- abdominal infections. 4. skin and skin structure infections. 5. bacterial septicaemia. 6. gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, tazopip is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. while tazopip is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta -lactamase producing piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to tazopip. therapy with tazopip may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the beta -lactamase producing organisms listed above. however, once these results become available, appropriate therapy should be continued. in serious infections, presumptive therapy with tazopip may be initiated before susceptibility test results are available. combination therapy with tazopip and aminoglycosides may be used in the treatment of serious infections caused by pseudomonas aeruginosa. both drugs should be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.